NASDAQ:AFMD
Affimed N.V. Stock Earnings Reports
$1.00
-0.0416 (-4.00%)
At Close: Feb 12, 2025
Affimed N.V. Earnings Calls
Q4 2024
(Upcoming)
Release date | Mar 27, 2025 |
EPS estimate | -$0.91 |
EPS actual | - |
Revenue estimate | 138.75K |
Revenue actual | - |
Expected change | +/- 11.80% |
Q3 2024
Beat
-$1.03 (9.65%)
Release date | Nov 14, 2024 |
EPS estimate | -$1.14 |
EPS actual | -$1.03 |
EPS Surprise | 9.65% |
Revenue estimate | 175.83K |
Revenue actual | 172.579K |
Revenue Surprise | -1.85% |
Q2 2024
Missed
-$1.09 (-9.00%)
Release date | Sep 05, 2024 |
EPS estimate | -$1.00 |
EPS actual | -$1.09 |
EPS Surprise | -9.00% |
Revenue estimate | 2.18M |
Revenue actual | 165.587K |
Revenue Surprise | -92.40% |
Q1 2024
Beat
-$1.38 (20.23%)
Release date | Jun 12, 2024 |
EPS estimate | -$1.73 |
EPS actual | -$1.38 |
EPS Surprise | 20.23% |
Revenue estimate | 458.575K |
Revenue actual | 166.513K |
Revenue Surprise | -63.69% |
Last 4 Quarters for Affimed N.V.
Below you can see how AFMD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
Release date | Jun 12, 2024 |
Fiscal end date | Mar 31, 2024 |
Price on release | $6.86 |
EPS estimate | -$1.73 |
EPS actual | -$1.38 |
EPS surprise | 20.23% |
Date | Price |
---|---|
Jun 06, 2024 | $6.31 |
Jun 07, 2024 | $6.14 |
Jun 10, 2024 | $6.12 |
Jun 11, 2024 | $6.53 |
Jun 12, 2024 | $6.86 |
Jun 13, 2024 | $7.09 |
Jun 14, 2024 | $7.10 |
Jun 17, 2024 | $6.74 |
Jun 18, 2024 | $6.05 |
4 days before | 8.72% |
4 days after | -11.81% |
On release day | 3.35% |
Change in period | -4.12% |
Q2 2024
Missed
Release date | Sep 05, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $3.79 |
EPS estimate | -$1.00 |
EPS actual | -$1.09 |
EPS surprise | -9.00% |
Date | Price |
---|---|
Aug 29, 2024 | $4.42 |
Aug 30, 2024 | $4.23 |
Sep 03, 2024 | $3.95 |
Sep 04, 2024 | $3.75 |
Sep 05, 2024 | $3.79 |
Sep 06, 2024 | $3.76 |
Sep 09, 2024 | $3.92 |
Sep 10, 2024 | $3.89 |
Sep 11, 2024 | $3.85 |
4 days before | -14.25% |
4 days after | 1.58% |
On release day | -0.792% |
Change in period | -12.90% |
Q3 2024
Beat
Release date | Nov 14, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $3.65 |
EPS estimate | -$1.14 |
EPS actual | -$1.03 |
EPS surprise | 9.65% |
Date | Price |
---|---|
Nov 08, 2024 | $3.85 |
Nov 11, 2024 | $3.82 |
Nov 12, 2024 | $3.77 |
Nov 13, 2024 | $3.75 |
Nov 14, 2024 | $3.65 |
Nov 15, 2024 | $3.48 |
Nov 18, 2024 | $3.16 |
Nov 19, 2024 | $3.00 |
Nov 20, 2024 | $2.72 |
4 days before | -5.19% |
4 days after | -25.48% |
On release day | -4.66% |
Change in period | -29.35% |
Q4 2024
(Upcoming)
Release date | Mar 27, 2025 |
Fiscal end date | Dec 30, 2024 |
Price on release | - |
EPS estimate | -$0.91 |
EPS actual | - |
Date | Price |
---|---|
Feb 06, 2025 | $1.05 |
Feb 07, 2025 | $1.05 |
Feb 10, 2025 | $1.04 |
Feb 11, 2025 | $1.04 |
Feb 12, 2025 | $1.00 |
Affimed N.V. Earnings Call Transcript Summary of Q3 2024
- Key Clinical Updates:
- Late-Stage Trials:
- AFM28 (CD123 targeting NK cell engager) and AFM24 (EGFR targeting NK cell engager) are progressing well, with promising data expected to be presented in December 2024.
- The combination of AFM24 and atezolizumab in non-small cell lung cancer (NSCLC) patients showed a promising disease control rate of 71% and a median progression-free survival (PFS) of 5.9 months.
- Upcoming Presentations:
- AFM28 will have an oral presentation at the ASH 2024 conference, with ongoing trials expected to generate robust data sets moving into pivotal studies.
- Late-Stage Trials:
- Financial Highlights:
- Affimed reported €24.1 million in cash at the end of Q3 2024, down from €72 million at the end of 2023.
- Net loss for the quarter was reduced to €15.1 million from €24.4 million year-over-year, indicating a focus on cost management and operational efficiency.
- Total revenue significantly decreased to €0.2 million from €2 million, reflecting a pivot in financial strategy towards long-term investments rather than immediate revenue generation.
- Strategic Focus and Future Planning:
- The company aims to enhance partnership opportunities and broaden its business development scope beyond traditional multinational partners, focusing on regional and co-development deals.
- Pursuing options to boost financial stability and extend the cash runway; partnerships are considered vital for this strategy.
- The emphasis is on generating differentiated clinical data that can support regulatory discussions for accelerated approvals, particularly for AFM28.
- Investor Considerations:
- Upcoming data presentations at ASH 2024 and key clinical updates in December will be critical for assessing the viability and future potential of Affimed's therapies.
- Investors are encouraged to monitor the maturation of clinical data, especially for pivotal trials that may lead to accelerated approval pathways.
- The company is poised to leverage promising initial results to attract potential partners seeking to invest in innovative cancer treatment solutions.
- Conclusion:
- Affimed remains committed to addressing unmet medical needs in oncology through innovative therapies while navigating strategic partnerships and maintaining a focus on financial health. The upcoming presentations and data releases will be crucial for shaping investor sentiment and the company’s market position.
Affimed N.V. Earnings History
Earnings Calendar
FAQ
When is the earnings report for AFMD?
Affimed N.V. (AFMD) has scheduled its earnings report for Mar 27, 2025 before the markets open.
What is the AFMD price-to-earnings (P/E) ratio?
AFMD P/E ratio as of Feb 12, 2025 (TTM) is -0.218.
What is the AFMD EPS forecast?
The forecasted EPS (Earnings Per Share) for Affimed N.V. (AFMD) for the first fiscal quarter 2024 is -$0.91.
What are Affimed N.V.'s retained earnings?
On its balance sheet, Affimed N.V. reported retained earnings of $172.58 thousand for the latest quarter ending Sep 30, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.